Physician profile
David Bornstein
NPI 1609439892
$5,970.13
in general payments reported to CMS, 2019-2025
36 companies · $70.10 in 2025
The $70.10 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,394 · 2022: $2,127 · 2023: $265 · 2024: $113 · 2025: $70.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $250 · Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $249.99 |
| Food and Beverage | $198.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,335.80 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $335.40 | 2021-2022 | |
| Incyte Corporation | $307.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $304.45 | 2021-2022 | |
| Pfizer INC. | $267.37 | 2021-2022 | |
| Lilly USA, LLC | $260.72 | 2021-2022 | |
| Abbvie INC. | $183.16 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.33 | 2021-2022 | |
| Myovant Sciences INC. | $145.07 | 2021-2022 | |
| Celgene Corporation | $134.14 | 2021-2022 | |
| Eisai INC. | $130.10 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $111.75 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $98.80 | 2021 | |
| Karyopharm Therapeutics INC. | $82.60 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $82.15 | 2021-2022 | |
| Puma Biotechnology, INC. | $75.71 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $75.22 | 2021-2022 | |
| Sobi, INC | $71.71 | 2022 | |
| Amgen INC. | $63.30 | 2022 | |
| Genzyme Corporation | $62.81 | 2021-2022 | |
| Dova Pharmaceuticals | $60.73 | 2021 | |
| Astellas Pharma US INC | $58.67 | 2021-2022 | |
| Morphosys, US INC. | $56.04 | 2021 | |
| Seagen INC. | $52.98 | 2021-2022 | |
| Beigene USA, INC. | $40.24 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $39.04 | 2021-2022 | |
| Array Biopharma INC | $38.39 | 2021-2022 | |
| Janssen Biotech, INC. | $36.86 | 2022 | |
| Emd Serono, INC. | $31.59 | 2021-2022 | |
| Taiho Oncology, INC. | $24.17 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.96 | 2021 | |
| Blueprint Medicines Corporation | $18.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.54 | 2022 | |
| Sumitomo Pharma America, INC. | $15.47 | 2023 | Orgovyx |
| Acrotech Biopharma INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bornstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.